# Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance

> **NCT07483983** · PHASE2 · RECRUITING · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 60 (estimated)

## Conditions studied

- Metastatic/Locally Advanced Non-Small-Cell Lung Cancer
- Metastatic/Locally Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** ASP3082

## Key facts

- **NCT ID:** NCT07483983
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2027-09
- **Final completion:** 2027-10
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07483983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07483983, "Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07483983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*